La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Betta Pharmaceuticals Crescita futura

Future criteri di controllo 4/6

Betta Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 28.4% e 18.1% all'anno. Si prevede che l'EPS crescerà di 28.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 10.1% in 3 anni.

Informazioni chiave

28.4%

Tasso di crescita degli utili

28.4%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	18.6%
Tasso di crescita dei ricavi	18.1%
Rendimento futuro del capitale proprio	10.1%
Copertura analitica	Low
Ultimo aggiornamento	06 Aug 2024

Aggiornamenti recenti sulla crescita futura

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 07

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Apr 23

Recent updates

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 07

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

Jul 30

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Jul 05

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Apr 26

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Apr 23

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Apr 16

Previsioni di crescita degli utili e dei ricavi

SZSE:300558 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	4,479	891	1,980	804	4
12/31/2025	3,656	626	1,617	1,249	5
12/31/2024	3,012	522	1,278	961	5
6/30/2024	2,643	424	164	1,076	N/A
3/31/2024	2,660	395	-80	1,023	N/A
12/31/2023	2,456	348	-182	914	N/A
9/30/2023	2,757	347	-304	657	N/A
6/30/2023	2,437	199	-588	539	N/A
3/31/2023	2,324	113	-623	415	N/A
12/31/2022	2,377	145	-704	307	N/A
9/30/2022	2,184	139	-797	276	N/A
6/30/2022	2,344	263	-530	426	N/A
3/31/2022	2,212	319	-373	478	N/A
1/1/2022	2,246	383	-232	527	N/A
9/30/2021	2,087	439	-95	616	N/A
6/30/2021	2,074	678	-227	521	N/A
3/31/2021	1,842	624	-317	439	N/A
12/31/2020	1,870	606	-40	646	N/A
9/30/2020	1,818	546	-22	656	N/A
6/30/2020	1,744	287	150	671	N/A
3/31/2020	1,826	310	220	739	N/A
12/31/2019	1,554	231	-65	555	N/A
9/30/2019	1,540	218	-178	448	N/A
6/30/2019	1,405	187	-291	375	N/A
3/31/2019	1,314	176	-368	314	N/A
12/31/2018	1,224	167	-328	286	N/A
9/30/2018	1,186	202	-322	313	N/A
6/30/2018	1,110	187	-359	316	N/A
3/31/2018	1,081	225	N/A	282	N/A
12/31/2017	1,026	258	N/A	278	N/A
9/30/2017	1,016	264	N/A	276	N/A
6/30/2017	1,015	294	N/A	302	N/A
3/31/2017	990	341	N/A	355	N/A
12/31/2016	1,035	369	N/A	407	N/A
9/30/2016	987	364	N/A	400	N/A
12/31/2015	915	345	N/A	386	N/A
12/31/2014	704	271	N/A	278	N/A
12/31/2013	481	180	N/A	190	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 300558 ( 28.4% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 300558 ( 28.4% all'anno) cresceranno più rapidamente del mercato CN ( 21.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 300558 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 300558 ( 18.1% all'anno) crescerà più rapidamente del mercato CN ( 13.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 300558 ( 18.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 300558 sarà basso tra 3 anni ( 10.1 %).

Betta Pharmaceuticals Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates increase by 15%, revenue downgraded

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Consensus EPS estimates fall by 17%

Price target decreased by 9.5% to CN¥51.64

Consensus EPS estimates increase by 20%, revenue downgraded

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Recent updates

Consensus EPS estimates increase by 15%, revenue downgraded

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

New minor risk - Earnings quality

Second quarter 2024 earnings: EPS exceeds analyst expectations

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Betta Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 06, 2024

Dividend increased to CN¥0.17

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares as Cash Dividend (Tax Included) for the Year 2023, Payable on 06 June 2024

Consensus EPS estimates fall by 17%

Price target decreased by 9.5% to CN¥51.64

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 20%, revenue downgraded

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Price target increased by 12% to CN¥65.00

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Betta Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 18%

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Consensus EPS estimates increase by 12%, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Betta Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Consensus EPS estimates fall by 13%

Price target decreased by 16% to CN¥57.04

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023

Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022

Price target increased by 13% to CN¥50.59

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Betta Pharmaceuticals Co., Ltd. Approves Board Elections

Insufficient new directors

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 11%

Price target decreased to CN¥57.39

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Betta Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 999.999991 million in funding

Investor sentiment improved over the past week

Betta Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Payable on 30 May 2022

High number of new and inexperienced directors

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 28, 2022

Betta Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Price target decreased to CN¥117

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.92 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.033 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.33 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.50 (vs CN¥0.58 in FY 2019)

New 90-day low: CN¥95.46

Investor sentiment deteriorated over the past week

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Analysts update estimates

Price target raised to CN¥97.57

New 90-day high: CN¥120

Market pulls back on stock over the past week

New 90-day low: CN¥99.80

Analysts update estimates

Third-quarter earnings released: Revenue and earnings beat expectations

Third quarter earnings released

New 90-day low: CN¥108

Analysts update estimates

New 90-day low - CN¥110

Ningbo Kaiming Innovation Technology Co., Ltd. completed the acquisition of Zhejiang Betta Pharmaceutical Technology Co., Ltd. from Betta Pharmaceuticals Co., Ltd. (SZSE:300558).